A new modality for immunosuppression: targeting the JAK/STAT pathway

Nat Rev Drug Discov. 2004 Jul;3(7):555-64. doi: 10.1038/nrd1441.

Authors

John J O'Shea¹, Marko Pesu, Dominic C Borie, Paul S Changelian

Affiliation

¹ Molecular Immunology and Inflammation Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. osheaj@arb.niams.nih.gov

PMID: 15232577
DOI: 10.1038/nrd1441

No abstract available

Publication types

Review

MeSH terms

Animals
Enzyme Inhibitors / chemistry
Enzyme Inhibitors / pharmacology*
Humans
Immunosuppression Therapy / methods*
Immunosuppressive Agents / chemistry
Immunosuppressive Agents / pharmacology*
Interleukin Receptor Common gamma Subunit
Janus Kinase 3
Molecular Structure
Mutation
Protein-Tyrosine Kinases / antagonists & inhibitors*
Protein-Tyrosine Kinases / genetics
Receptors, Interleukin-7 / genetics
Receptors, Interleukin-7 / immunology*
Severe Combined Immunodeficiency / drug therapy
Severe Combined Immunodeficiency / enzymology
Signal Transduction / drug effects*
Signal Transduction / immunology
Trans-Activators / antagonists & inhibitors*

Substances

Enzyme Inhibitors
IL2RG protein, human
Immunosuppressive Agents
Interleukin Receptor Common gamma Subunit
Receptors, Interleukin-7
Trans-Activators
Protein-Tyrosine Kinases
JAK3 protein, human
Janus Kinase 3